InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
September 08 2008 - 9:15AM
PR Newswire (US)
BRITISH COLUMBIA, Canada, Sept. 8 /PRNewswire-FirstCall/ -- InNexus
Biotechnology Inc. (TSX: IXS.V; OTC Bulletin Board: IXSBF)
(http://www.ixsbio.com/), a drug development company
commercializing the next generation of monoclonal antibodies based
on its Dynamic Cross Linking (DXL(TM)) technology, announces Jeff
Morhet, CEO and Chairman, to present during the Wall Street Analyst
Forum at the University Club in New York City, Wednesday, September
10, 2008. CEO and Chairman, Jeff Morhet will provide a company
overview, including information about InNexus' unique business
strategy, its DXL(TM) technology platform and upcoming company
milestones. Investors, venture capitalists, company executives,
scientists and other industry leaders will attend the conferences.
The Wall Street Analyst Forum has been a sponsor of annual analyst
conferences for NYSE/NASDAQ/AMEX corporations in New York, Boston
and London since 1988. The conferences support participating
companies by inviting all buy/sell side analyst and portfolio
managers to attend while leveraging the use of three new media
channels. Over 2,500 public corporations have presented ranging
from General Electric, Nokia, Pfizer, Motorola, Inc., Unilever, KB
Homes to Adobe Systems. A live web cast is also available to view
online at http://wsw.com/webcast/wsaf7/. Mr. Morhet will be
presenting from 9:50-10:30 AM EDT on Wednesday, September 10th.
About InNexus InNexus is a drug development company commercializing
the next generation of monoclonal antibodies based on its DXL(TM)
technology, which improves the potency of existing antibody
products while opening new markets and disease applications.
DXL(TM) antibodies utilize unique, novel and patented methods and
technologies of InNexus. InNexus is headquartered in British
Columbia with principal management based in Scottsdale, Arizona on
the campus of Mayo Clinic and has its own in-house developmental
facilities. These development resources provide validation of
protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and
diagnostics. To learn more about InNexus, please visit
http://www.ixsbio.com/. The TSX Venture Exchange has not reviewed
and does not accept responsibility for the adequacy or accuracy of
this news release. This news release may contain assumptions,
estimates, and other forward-looking statements that involve
inherent risks and uncertainties and are subject to factors, many
of which are beyond the Company's control, which may cause actual
results or performance to differ materially from those currently
anticipated in such statements. DATASOURCE: InNexus Biotechnology
Inc. CONTACT: Jeff Morhet, Chairman & Chief Executive Officer
of InNexus Biotechnology Inc., +1-480-862-7500 Web site:
http://www.ixsbio.com/ http://wsw.com/webcast/wsaf7
Copyright